MohiniRanganathanMD

Assistant Professor, Psychiatry, Yale University School of Medicine

Dr. Ranganathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
950 Campbell Ave
Psychiatry Service/116a
West Haven, CT 06516
Phone+1 203-932-5711

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Start of enrollment: 2009 Feb 01
Completed
Phase 2
Effects of Salvinorin A in Healthy Controls Start of enrollment: 2009 Feb 12
Completed
Early Phase 1
The Effects of Cannabidiol and ∆-9-THC in Humans Start of enrollment: 2010 Feb 01
Completed
Early Phase 1
Cannabinoid Augmentation of Fear Response in Humans Start of enrollment: 2012 Jul 17
Completed
Early Phase 1
Probing the Cannabinoid System in Individuals With a Family History of Psychosis Start of enrollment: 2014 Jan 01
Active, not recruiting
Early Phase 1
Open Label Ketamine Treatment for Major Depressive Disorder in Veterans Start of enrollment: 2017 Jan 31
Completed
Phase 2
The Neural Correlates of Cannabis Use Start of enrollment: 2016 Dec 01
Completed
CB1R in Synthetic Psychoactive Cannabinoids Start of enrollment: 2018 May 01
Active, not recruiting
Not Applicable
BXCL501 for Agitation in Schizophrenia Start of enrollment: 2020 Mar 09
Recruiting
Phase 2
Join now to see all

PubMed

Journal Articles

Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia
Mohini Ranganathan, John H Krystal, JAMA Network Open

Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020
Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding SchizophreniaMay 2020

Cannabidiol Drugs Clinical Trial Outcomes and Adverse EffectsFebruary 25th, 2020
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)December 29th, 2017
Why Some People Can't Handle Their WeedMay 15th, 2017
Join now to see all